



LKT Laboratories, Inc.

SB-202190

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID S041001

CAS No. 152121-30-7

Chemical Name 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol

Synonym SB202190; SB 202190; FHPI; UNII-PVX798P8GI ; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole

Formula C₂₀H₁₄FN₃O

Formula Wt. 331.35

Melting Point


Purity ≥99%

Solubility Soluble in DMSO to 100 mM, 20mg/mL in ethanol, 2mg/mL in Ethyl acetate

Store Temp

Ship Temp Ambient

Description SB-202190 is a highly selective p38 MAPK inhibitor. In a rabbit model, treatment with SB-202190 after filtering glaucoma surgery improved bleb characteristics and intraocular pressure. In a chronic hypoperfusion rat model of vascular dementia, treatment with SB-202190 reduced apoptosis of hippocampal neurons and rescued spatial learning and memory deficits.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
S041001	5 mg	\$60.90
S041001	25 mg	\$183.80
S041001	100 mg	\$551.30

References Nassar K, Tura A, Luke J, et al. A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery. J Glaucoma. 2015 Feb;24(2):165-178. PMID: 25493622.

Yang S, Zhou G, Liu H, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798. PMID: 24455679.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.